Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants

Liver Transplantation

Volumn 11, Issue 5, 2005, Pages 532-538

  Marzano, Alfredo ^a   Lampertico, Pietro ^b   Mazzaferro, Vincenzo ^c   Carenzi, Silvia ^a   Vigano, Mauro ^b   Romito, Raffaele ^c   Pulvirenti, Andrea ^c   Franchello, Alessandro ^a   Colombo, Massimo ^b   Salizzoni, Mauro ^a   Rizzetto, Mario ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ASPARTIC ACID; CYCLOSPORIN A; HEPATITIS B ANTIBODY; LAMIVUDINE; METHIONINE; STEROID; TYROSINE; VENBIG; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY DISEASE; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MENTAL DISEASE; PHENOTYPE; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTANT; VIRUS RESISTANCE;

ADENINE; ADULT; ANTIBODIES, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHENOTYPE; PHOSPHONIC ACIDS; RECURRENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 21044434308     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20393     Document Type: Article

References (25)

1. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
2. Mutimer D, Pillay D, Dragon E, Tang H, Ahmed M, O'Donnell K, et al. High pre-treatment serum hepatitis B virus titer predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999;30:715-721.
3. Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000;46:107-113.
4. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998;27:213-222.
5. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine clinical investigation group. Hepatology 1998;27:1670-1677.
6. EASL international consensus conference on hepatitis B. J Hepatol 2003;38:533-540.
7. Conjeevaram HS, Lok ASF. Management of chronic hepatitis B. J Hepatol 2003;38:S90-S103.
8. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence after liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998;28:585-589.
9. Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999,5:491-496.
10. Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto L, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999;6:520-525.
11. McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999;6:512-519.
12. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence in cirrhotic patients treated with lamivudine before surgery and combined with passive immunoprophylaxis after liver transplantation. J Hepatol 2001;34:903-910.
13. Rosenau J, Bahr MJ, Tilmann HL, Trautwein C, Klempnauer J, Manns MP, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B infection after liver transplantation: possible role of mutations in the YMDD motif before transplantation as a risk factor for reinfection. J Hepatol 2001; 34:895-902.
14. Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35:1528-1535.
15. Saab S, Kim M, Wright TL, Han SH, Martin P, Busuttil RWl. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 2000; 119:1382-1384.
16. Starkel P, Horsmans Y, Geubel A, Ciccarelli O, Goubau P, Rahier J, Lerut J. Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure because of the emergence of a hepatitis B YMDD escape mutant virus. J Hepatol 2001;35:679-681.
17. Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, et al. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. Am J Gastroenterol 2003;98:151-159.
18. Gaia S, Marzano A, Smedile A, Barbon V, Abate M, Olivero A, et al. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2004;20:281-287.
19. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348: 808-816.
20. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
21. Peters MG, Singer G, Howard T, Jacobsmeyer S, Xiong X, Gibbs CS, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999;68:1912-1914.
22. Peters MG, Singer G, Howard T, Jacobsmeyer S, Xiong X, Gibbs CS, et al. Adefovir dipivoxil for treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134.
23. Marzano A, Ciancio A, Salizzoni M, Rizzetto M, Negro F. Hepatitis B virus subtypes and lamivudine resistance. Lancet 2001; 358:153-154.
24. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419-1427.
25. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.